The article by Zhao et al. titled “Associations of Triglyceride-Glucose (TyG) Index with Chest Pain Incidence and Mortality among the U.S. Population” provides valuable insights into the positive correlation between the TyG index and chest pain incidence, as well as a nonlinear relationship with mortality. However, the use of the COX proportional hazards model in their analysis presents several limitations. The assumption of constant hazard ratios over time may not hold, potentially leading to biased estimates. The model’s struggle with time-dependent covariates and the possibility of residual confounding are notable concerns. Additionally, the study’s subgroup analyses might suffer from reduced statistical power, and potential interactions with other metabolic markers were not explored. Considering these limitations, future research should adopt alternative approaches, such as time-varying covariate models, to provide a more comprehensive understanding of the relationship between the TyG index and cardiovascular outcomes.

This study investigates the differences between COVID-19 and past common forms of pneumonia and to determine if COVID-19 acts as a contributing factor in various cardiovascular diseases (CVDs). We retrieved large-sample genome-wide association study data from the Open GWAS database related to COVID-19, bacterial pneumonia (BP), viral pneumonia (VP), stable angina (SA), unstable angina (UA), heart failure (HF), ischemic heart disease (IHD), atrial fibrillation (AF), and myocardial infarction (MI). We selected single-nucleotide polymorphisms with strong correlations as instrumental variables (P < 5E-06), and set the threshold for the F-statistic to be over 10. Five statistical methods were used for analysis including inverse variance weighted, Mendelian randomization-Egger, weighted median, simple mode, and weighted mode, with inverse variance weighted as the primary method. We assessed the reliability of our results through heterogeneity, pleiotropy, and sensitivity testing; Our analysis probed the relationship between COVID-19, BP, VP, and 6 CVDs. COVID-19 infection was found to enhance the incidence of SA, UA, HF, and MI (SA: odds ratio [OR], 1.12; 95% confidence interval [CI], 1.04–1.20; P = .002; UA: OR, 1.14; 95% CI, 1.01–1.29; P = .041; HF: OR, 1.12; 95% CI, 1.03–1.23; P = .012; MI: OR, 1.11; 95% CI, 1.02–1.25; P = .032). There was no significant effect on the incidence of AF or IHD (P > .05), and no pleiotropy or sensitivity issues were found in the results. In contrast, neither past common BP nor VP was found to contribute to the progression of these 6 CVDs (P > .05). Unlike past common BP or VP, COVID-19 was found to increase the risks of SA, UA, HF, and MI, with no evidence supporting an increased risk for AF or IHD following COVID-19 infection.

Diabetic cardiomyopathy (DCM) is one of the crucial causes leading to heart failure and adverse outcomes in patients with diabetes mellitus; however, effective strategies targeting its molecular pathological mechanisms and therapies are currently lacking. DCM is primarily characterized by early diastolic dysfunction, cardiomyocyte apoptosis, and fibrosis. Its disease progression is relatively insidious, eventually evolving into heart failure with preserved ejection fraction. The intrinsic metabolic environment of diabetes markedly exacerbates oxidative stress, and the accumulated polyunsaturated fatty acids within cardiomyocytes are highly susceptible to lipid peroxidation, leading to the excessive generation of 4-hydroxy-2-nonenal (4-HNE). The pivotal role of this reactive aldehyde in promoting the progression of DCM has been extensively demonstrated in animal, cellular, and clinical models. However, its subcellular targets and the underlying molecular mechanisms remain inadequately elucidated. Organelles, as central executors of diverse intracellular functions, may serve as potential sites of 4-HNE-induced interference and therapeutic targeting. This article focuses on the central role of 4-HNE in triggering energy depletion, calcium overload, autophagic flux blockade, and ferroptosis through its interactions among mitochondria, endoplasmic reticulum, lysosomes, and other organelles. On the basis of existing evidence, potentially translatable therapeutic avenues include ALDH2 activators, G protein–coupled receptor 40 (GPR40) agonists, mitochondria-targeted antioxidants and ferroptosis inhibitors. The aim is to provide a theoretical foundation and reference for the clinical identification of myocardial injury in DCM, model replication, and the development of targeted intervention strategies.